Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
covid-19_vaccines:adverse_events:myocarditis [2022/01/27 17:50] brian [Research] | covid-19_vaccines:adverse_events:myocarditis [2022/07/15 06:21] (current) liam |
---|
====== COVID-19 Vaccine Associated Myocarditis ====== | ====== COVID-19 Vaccine Associated Myocarditis ====== |
| |
During the experimental [[:COVID-19 vaccines]] campaign, many vaccine recipients have suffered vaccine-associated [[:myocarditis]]. There is a debate over the nature of the damage caused in these cases of myocarditis as well as the relative risk of myocarditis associated with [[:SARS-CoV-2]] infection or [[:COVID-19]] cases. | During the experimental [[:COVID-19 vaccines]] campaign, many vaccine recipients have suffered vaccine-associated [[:myocarditis]]. There is a debate over the nature of the damage caused in these cases of myocarditis as well as the relative risk of myocarditis associated with [[:SARS-CoV-2]] infection or [[:COVID-19]] cases. |
| |
| |
===== Research ===== | ===== Research ===== |
| |
Increased occurrence of myocarditis, pericarditis and myopericarditis has been associated with Covid-19 inoculations,((https://www.nature.com/articles/s41591-021-01630-0)) along with Covid-19 infection. | Increased occurrence of myocarditis, pericarditis and myopericarditis has been associated with Covid-19 inoculations,((https://www.nature.com/articles/s41591-021-01630-0)) along with Covid-19 infection. |
| |
{{ :myocarditis_vaers.jpg?600 |}} | {{ :myocarditis_vaers.jpg?600 |}} |
| |
| ^ Incidence of Myocarditis Following the Second Dose of a Covid-19 mRNA Vaccine ^^^^^^^^^ |
^ Incidence of Myocarditis Following the Second Dose of a Covid-19 mRNA Vaccine ^^^^^^^^ | ^ ^ Male: Age 12-15 ^ Male: Age 12-17 ^ Male: Age 16-17 ^ Male: Age 16-19 ^ Male: Age 18-24 ^ Male: Age < 30 ^ Male: Age < 40 ^ Rate from Sars-cov-2 ^ |
^ ^ Male: Age 12-15 ^ Male: Age 12-17 ^ Male: Age 16-17 ^ Male: Age 18-24 ^ Male: Age < 30 ^ Male: Age < 40 ^ Rate from Sars-cov-2 ^ | |
| Kaiser Permanente Study - Dec 27, 2021((https://www.medrxiv.org/content/10.1101/2021.12.21.21268209v1))| - | 1 / 1860 | 1 / 2650 | | | Kaiser Permanente Study - Dec 27, 2021((https://www.medrxiv.org/content/10.1101/2021.12.21.21268209v1))| - | 1 / 1860 | 1 / 2650 | |
| Nature Medicine Paper - Dec 25, 2021((https://www.medrxiv.org/content/10.1101/2021.12.23.21268276v1))| - | | - | 101 excess events per million (Moderna) | 30 excess events per million | | | Nature Medicine Paper - Dec 25, 2021((https://www.medrxiv.org/content/10.1101/2021.12.23.21268276v1))| - | | - | 101 excess events per million (Moderna) | 30 excess events per million | |
| USA FDA ACIP Meeting Presentation((http://dx.doi.org/10.15585/mmwr.mm7027e2)) | | | 62.8 per million | | 50.5 per million | | | USA FDA ACIP Meeting Presentation((http://dx.doi.org/10.15585/mmwr.mm7027e2)) | | | 62.8 per million | | 50.5 per million | |
| Israel MoH((https://www.nejm.org/doi/full/10.1056/NEJMc2116999?query=featured_home)) | 1 / 12,361 | | | Israel MoH((https://www.nejm.org/doi/full/10.1056/NEJMc2116999?query=featured_home)) | 1 / 12,361 | |
| Oster, CDC((https://jamanetwork.com/journals/jama/fullarticle/2788346)) | 71 per million (pfizer) | 106 per million (pfizer) | | 56 per million (moderna) | | | Oster, CDC((https://jamanetwork.com/journals/jama/fullarticle/2788346)) | 71 per million (pfizer) | 106 per million (pfizer) | | | 56 per million (moderna) | |
| | Mevorach, Israel((https://www.nejm.org/doi/full/10.1056/NEJMoa2109730)) | - | - | - | 1 / 6637 | |
| |
| A research letter published by JAMA claimed that rates of myocarditis and pericarditis increased less than 100% post-vaccination.((August 4, 2021 | George A. Diaz et al | [[:JAMA]] | Myocarditis and Pericarditis After Vaccination for COVID-19 | [[https://jamanetwork.com/journals/jama/fullarticle/2782900|doi:10.1001/jama.2021.13443]])) |
| |
==== CDC Reports ==== | ==== CDC Reports ==== |
The CDC continued to recommend use of these vaccinations while urging doctors to follow a list of clinical guidelines and to make VAERS reports as needed. ((https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html)) | The CDC continued to recommend use of these vaccinations while urging doctors to follow a list of clinical guidelines and to make VAERS reports as needed. ((https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html)) |
| |
In the December 31, 2020 MMWR the CDC released information related to COVID-19 vaccine safety in children aged 5–11 years, covering the November 3–December 19, 2021 period of slightly over a five weeks. The information was drawn from VEARS and VSAFE and was restricted to those who received Pfizer-BioNTech COVID-19 vaccine. ((https://www.cdc.gov/mmwr/volumes/70/wr/mm705152a1.htm)) | In the December 31, 2021 MMWR the CDC released information related to COVID-19 vaccine safety in children aged 5–11 years, covering the November 3–December 19, 2021 period of slightly over a five weeks. The information was drawn from VEARS and VSAFE and was restricted to those who received Pfizer-BioNTech COVID-19 vaccine. ((https://www.cdc.gov/mmwr/volumes/70/wr/mm705152a1.htm)) |
| |
==== Small Hong Kong Studies ==== | ==== Small Hong Kong Studies ==== |
| |
[[https://www.nejm.org/doi/full/10.1056/NEJMc2116999?query=featured_home|Myocarditis after BNT162b2 Vaccination in Israeli Adolescents]] | [[https://www.nejm.org/doi/full/10.1056/NEJMc2116999?query=featured_home|Myocarditis after BNT162b2 Vaccination in Israeli Adolescents]] |
| |
| [[https://pubmed.ncbi.nlm.nih.gov/35404496/|Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods]] |
| |
===== Link dump ===== | ===== Link dump ===== |